Cardiff Oncology, Inc. $CRDF Shares Purchased by MetLife Investment Management LLC

MetLife Investment Management LLC lifted its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 34.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,726 shares of the company’s stock after purchasing an additional 9,167 shares during the quarter. MetLife Investment Management LLC owned about 0.05% of Cardiff Oncology worth $112,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Nuveen LLC acquired a new stake in shares of Cardiff Oncology in the 1st quarter worth $2,693,000. Charles Schwab Investment Management Inc. boosted its position in shares of Cardiff Oncology by 67.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 169,974 shares of the company’s stock worth $534,000 after purchasing an additional 68,310 shares in the last quarter. Blair William & Co. IL boosted its position in shares of Cardiff Oncology by 521.0% in the 1st quarter. Blair William & Co. IL now owns 1,751,274 shares of the company’s stock worth $5,499,000 after purchasing an additional 1,469,249 shares in the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of Cardiff Oncology in the 1st quarter worth $302,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Cardiff Oncology by 12.0% in the 1st quarter. Bank of New York Mellon Corp now owns 323,347 shares of the company’s stock worth $1,015,000 after purchasing an additional 34,732 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright lowered their price objective on Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. LADENBURG THALM/SH SH initiated coverage on Cardiff Oncology in a research note on Tuesday, July 8th. They issued a “buy” rating and a $19.00 target price for the company. Jefferies Financial Group initiated coverage on Cardiff Oncology in a research note on Tuesday, June 24th. They issued a “hold” rating and a $3.50 target price for the company. Finally, William Blair restated an “outperform” rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.63.

Insider Buying and Selling at Cardiff Oncology

In related news, Director Gary W. Pace acquired 275,000 shares of Cardiff Oncology stock in a transaction on Wednesday, July 30th. The stock was acquired at an average price of $2.45 per share, for a total transaction of $673,750.00. Following the purchase, the director owned 1,330,676 shares of the company’s stock, valued at approximately $3,260,156.20. This represents a 26.05% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 7.70% of the company’s stock.

Cardiff Oncology Stock Performance

NASDAQ CRDF opened at $2.04 on Thursday. The stock has a 50-day simple moving average of $2.93 and a two-hundred day simple moving average of $3.16. The firm has a market capitalization of $135.72 million, a P/E ratio of -2.34 and a beta of 1.28. Cardiff Oncology, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.11 million. Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. As a group, analysts forecast that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.